Proxima

VantAI, a subsidiary of Roivant Sciences, is dedicated to using machine learning to design and optimize induced proximity drugs. The company's evolutionary scoring system draws from naturally occurring protein interaction interfaces, enabling generative models to design smaller molecular weight molecular glues that form highly cooperative ternary complexes. VantAI has collaborated with numerous biopharmaceutical partners to initiate exciting new development projects through its unique "Protein-Contact-First" strategy, requiring only a fraction of the time and cost of traditional methods.